Dysphagia Outcomes Following Surgical Management of Unilateral Vocal Fold Immobility: A Systematic Review and Meta-analysis

2022 ◽  
pp. 019459982110728
Author(s):  
Michael Coulter ◽  
Kastley Marvin ◽  
Matthew Brigger ◽  
Christopher M. Johnson

Objective To assess dysphagia outcomes following surgical management of unilateral vocal fold immobility (UVFI) in adults. Data Sources Ovid MEDLINE, Embase, Web of Science, and Cochrane Central. Review Methods A structured literature search was utilized, and a 2-researcher systematic review was performed following PRISMA guidelines. Extractable data were pooled, and a quantitative analysis was performed with a random effects model to analyze treatment outcome and complications by procedure. Results A total of 416 publications were screened and 26 met inclusion criteria. Subjects encompassed 959 patients with UVFI who underwent 916 procedures (n = 547, injection laryngoplasty; n = 357, laryngeal framework surgery; n = 12, laryngeal reinnervation). An overall 615 were identified as having dysphagia as a result of UVFI and had individually extractable outcome data, which served as the basis for a quantitative meta-analysis. In general, dysphagia outcomes after all medialization procedures were strongly positive. Quantitative analysis demonstrated a success rate estimate of 90% (95% CI, 75%-100%) for injection laryngoplasty and 92% (95% CI, 87%-97%) for laryngeal framework surgery. The estimated complication rate was 7% (95% CI, 2%-13%) for injection laryngoplasty and 15% (95% CI, 10%-20%) for laryngeal framework surgery, with minor complications predominating. Although laryngeal reinnervation could not be assessed quantitatively due to low numbers, qualitative analysis demonstrated consistent benefit for a majority of patients for each procedure. Conclusion Dysphagia due to UVFI can be improved in a majority of patients with surgical procedures intended to improve glottal competence, with a low risk of complications. Injection laryngoplasty and laryngeal framework surgery appear to be efficacious and safe, and laryngeal reinnervation may be a promising new option for select patients.

Cells ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 2417
Author(s):  
Chen-Chi Wang ◽  
Shang-Heng Wu ◽  
Yu-Kang Tu ◽  
Wen-Jiun Lin ◽  
Shih-An Liu

Unilateral vocal fold paralysis (UVFP) is a common disorder that may cause glottal closure insufficiency and then hoarseness of voice and aspiration during swallowing. We conducted a systematic review and meta-analysis to evaluate whether hyaluronic acid (HA) injection laryngoplasty (IL) is an effective treatment for patients with UVFP. Comprehensive systematic searches were undertaken using PubMed, EBSCO Medline, and Cochrane Library databases. We appraised the quality of studies according to preset inclusion and exclusion criteria. The lengths of follow-up were divided into “short-term” (3 months or shorter), “medium-term” (6 months), and “long-term” (12 months or longer). We performed random-effect meta-analysis to estimate the changes in voice-related quality of life, perceptual evaluation by grading systems, voice lab analysis of maximal phonation time, and normalized glottal gap area, before and after HA IL. Fourteen studies were eligible for the final analysis. The results showed that patients’ glottal closure insufficiency could be improved; maximal phonation time could be prolonged; perceptual evaluations of the voice and quality of life were better after HA IL, but the duration of treatment effect varied among different studies. In conclusion, HA IL is an effective treatment for UVFP, which may achieve a long-term effect and therefore reduce the likelihood of requiring permanent medialization thyroplasty.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Claudia Cristina Biguetti ◽  
Joel Ferreira Santiago Junior ◽  
Matthew William Fiedler ◽  
Mauro Toledo Marrelli ◽  
Marco Brotto

AbstractThe aim of this systematic review was to perform qualitative and quantitative analysis on the toxic effects of chloroquine (CQ) and hydroxychloroquine (HCQ) on skeletal muscles. We designed the study according to PRISMA guidelines. Studies for qualitative and quantitative analyses were selected according to the following inclusion criteria: English language; size of sample (> 5 patients), adult (> age of 18) patients, treated with CQ/HCQ for inflammatory diseases, and presenting and not presenting with toxic effects on skeletal muscles. We collected data published from 1990 to April 2020 using PubMed, Cochrane Library, EMBASE, and SciELO. Risk of bias for observational studies was assessed regarding the ROBIN-I scale. Studies with less than five patients (case reports) were selected for an additional qualitative analysis. We used the software Comprehensive Meta-Analysis at the confidence level of 0.05. We identified 23 studies for qualitative analysis (17 case-reports), and five studies were eligible for quantitative analysis. From case reports, 21 patients presented muscle weakness and confirmatory biopsy for CQ/HCQ induced myopathy. From observational studies, 37 patients out of 1,367 patients from five studies presented muscle weakness related to the use of CQ/HCQ, and 252 patients presented elevated levels of muscle enzymes (aldolase, creatine phosphokinase, and lactate dehydrogenase). Four studies presented data on 34 patients with confirmatory biopsy for drug-induced myopathy. No study presented randomized samples. The chronic use of CQ/HCQ may be a risk for drug-induced myopathy. There is substantiated need for proper randomized trials and controlled prospective studies needed to assess the clinical and subclinical stages of CQ/HCQ -induced muscle myopathy.


2019 ◽  
Vol 69 (6) ◽  
pp. 2004
Author(s):  
V. Robertson ◽  
F. Poli ◽  
B. Hobson ◽  
A. Saratzis ◽  
A. Ross Naylor

PLoS ONE ◽  
2019 ◽  
Vol 14 (7) ◽  
pp. e0217775
Author(s):  
Emma R. Allanson ◽  
Aime Powell ◽  
Max Bulsara ◽  
Hong Lim Lee ◽  
Lynette Denny ◽  
...  

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e14037-e14037
Author(s):  
Bhavina D O Batukbhai ◽  
Madeleine Champagne ◽  
Karan Rai ◽  
Odeth Barrett-Campbell ◽  
Natalie Riblet

e14037 Background: Malnutrition is a common finding seen in 50-80% of cancer patients. Malnutrition negatively impacts quality of life (QOL), treatment-related outcomes, and survival. While early nutrition interventions (ENI) may be beneficial in preventing malnutrition, they are not part of routine cancer care. We conducted a systematic review and meta-analysis to assess the benefits of ENI compared to standard of care (SC) on nutritional status, QOL, and survival in patients with newly diagnosed cancer. Methods: We searched MEDLINE, EMBASE, Cochrane, and CINAHL databases from inception through October 2019 to identify randomized control trials (RCT) and cohort studies comparing ENI to SC in adult patients with newly diagnosed oncologic malignancies. We required that nutrition interventions began within 8 weeks of diagnosis and lasted at least 6 weeks. Outcomes of interest included nutritional status (change in weight or BMI), mortality, and QOL. We assessed for risk of bias among included studies using the Cochrane Risk of Bias tool (RCT) and the Newcastle-Ottawa scale (cohort studies). We summarized change in weight (kilogram, kg) at 3 and 6 months using standardized mean differences (SMD) and 95% Confidence Intervals (CI). Because some studies had insufficient data on weight to allow for quantitative analysis, we summarized their findings qualitatively. We used a qualitative approach to summarize QOL. Mortality at 1 and 2 years was compared using relative risk (RR) and 95%CI. Random effects models were used to pool data as there was meaningful and statistically significant heterogeneity (I2 > 50%; p-value < 0.1). Results: 2,781 studies were identified and screened by two independent reviewers for eligibility. 18 independent studies (subjects = 1936) met inclusion criteria. Among 9 studies included in the quantitative analysis for nutritional status, patients who received ENI had better nutritional status compared to SC (SMD at 3 months 0.49kg, 95%CI 0.08-0.79; at 6 months: 0.27kg, 95% CI 0.09-0.45). ENI was also associated with a lower risk of death compared to SC, although the findings were not significant (1 year RR: 0.41[95% CI 0.09-1.81]; 2 year RR: 0.79 [95 CI 0.58-1.09]). Of the ten studies reporting on QOL, six found that patients in the ENI group had improved QOL outcomes. There was insufficient data available to perform subgroup analysis based on cancer type. The quality of studies was generally good and 11 of the included studies had low risk of bias. Conclusions: Patients with newly diagnosed cancer may benefit from ENI due to better weight outcomes, QOL, and survival.


2013 ◽  
Vol 105 (3) ◽  
pp. 377-383 ◽  
Author(s):  
Kai Zhang ◽  
Wen-han Hu ◽  
Chao Zhang ◽  
Fan-gang Meng ◽  
Ning Chen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document